Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome

Endocrine Journal

Volumn 59, Issue 1, 2012, Pages 21-29

  Koiou, Ekaterini ^a   Tziomalos, Konstantinos ^a   Dinas, Konstantinos ^a   Katsikis, Ilias ^a   Kandaraki, Eleni A ^a   Tsourdi, Elena ^a   Mavridis, Stylianos ^a   Panidis, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Insulin resistance; Obesity; Phenotypes; Plasminogen activator inhibitor 1; Polycystic ovary syndrome

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANOVULATION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PLASMINOGEN ACTIVATOR INHIBITOR 1 BLOOD LEVEL; PROTEIN BLOOD LEVEL;

ADIPOSITY; ADULT; ANOVULATION; BIOLOGICAL MARKERS; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; OBESITY; OVERWEIGHT; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 84856805791     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0023     Document Type: Article

References (36)

1. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685-697.
2. Zawadski JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE, Hershman SM (eds) Polycystic ovary syndrome. Current issues in Endocrinology and Metabolism. Blackwell, Boston: 377-384.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47.
4. Diamanti-Kandarakis E, Panidis D (2007) Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 67:735-742.
5. Moran L, Teede H (2009) Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 15:477-488.
6. Carmina E, Lobo RA (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82:661-665.
7. Cesari M, Pahor M, Incalzi RA (2010) Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fbrin-olysis and age-related subclinical and clinical conditions. Cardiovasc Ther 28:e72-91.
8. Festa A, D'Agostino R, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137.
9. Meigs JB, O'donnell CJ, Tofer GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW (2006) Hemostatic markers of endothe-lial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530-537.
10. Baillargeon JP, Carpentier A (2007) Role of insulin in the hyperandrogenemia of lean women with polycys-tic ovary syndrome and normal insulin sensitivity. Fertil Steril 88:886-893.
11. González F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic infammation in polycystic ovary syndrome. Metabolism 58:954-962.
12. Lindholm A, Bixo M, Eliasson M, Hudecova M, Arnadottir R, Holte J, Poromaa IS (2010) Tissue plas-minogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol 26:743-748.
13. Orio F Jr, Palomba S, Cascella T, Tauchmanovà L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A, Lombardi G (2004) Is plas-minogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 9:505-510.
14. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce frst-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46-52.
15. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, Lehnert H, Randeva HS (2009) Metformin decreases angiogenesis via NF-kappaB and Erk1/2/ Erk5 pathways by increasing the antiangiogenic throm-bospondin-1. Cardiovasc Res 83:566-574.
16. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ (2009) A comprehensive assessment of endothelial function in overweight women with and without poly-cystic ovary syndrome. Clin Sci (Lond) 116:761-770.
17. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D (2009) Anti-Müllerian hormone levels refect severity of PCOS but are negatively infuenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 296:E238-243.
18. Carter GD, Holland SM, Alaghband-Zadeh J, Rayman G, Dorrington-Ward P, Wise PH (1983) Investigation of hirsutism: testosterone is not enough. Ann Clin Biochem 20:262-263.
19. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:12-19.
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410.
21. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS (1996) Ambulatory blood pressure profles and plasmi-nogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 45:623-629.
22. Tarkun I, Cantürk Z, Arslan BC, Türemen E, Tarkun P (2004) The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 51:467-472.
23. Słopień R, Lewandowski K, Kolacz E, Zawilska K, Warenik-Szymankiewicz A (2006) Comparison of fbrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Gynecol Endocrinol 22:651-654.
24. Andersen P, Seljefot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, Birkeland K (1995) Increased insulin sensitivity and fbrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44:611-616.
25. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F (2005) Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril 84:761-765.
26. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G (2004) Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:1273-1276.
27. DeFronzo RA,Tobin JD, Andres R (1979) Glucoseclamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223.
28. Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E (2011) Coagulation and fbrinolytic disturbances in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96:1068-1076.
29. Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, Pedrinelli R, Dell'Omo G, Bersi C (2005) Insulin resistance causes impaired vaso-dilation and hypofbrinolysis in young women with polycystic ovary syndrome. Thromb Res 116:207-214.
30. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF (2006) Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 6:77-83.
31. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95:2038-2049.
32. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ (2008) Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93:1276-1284.
33. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH (2004) Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25:252-259.
34. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112:3080-3087.
35. Wang TJ, Gona P, Larson MG, Tofer GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS (2006) Multiple biomarkers for the prediction of frst major cardiovascular events and death. N Engl J Med 355:2631-2639.
36. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG (1998) The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 69:236-241.